A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Prior treatment

• Not recovered from the effects of prior anticancer therapy
• Major surgery within 30 days of administration of first dose
• Should not have received any prior selective investigational inhibitors or degraders (Part 5 only)

Other illness

• History of another malignancy except for the following: adequately treated local basal cell or squamous carcinoma of the skin, in situ cervical cancer, adequately treated papillary noninvasive bladder cancer, other adequately treated Stage I or Stage II cancers currently in complete remission
• Clinically significant cardiovascular event, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months
• Active interstitial lung disease requiring treatment
• History of uveitis, retinopathy, or other clinically significant retinal disease
• Active uncontrolled infectious disease
• Significant liver disease (Child Pugh class B or C)

Other

• Advanced solid tumor that is a candidate for curative treatment
• Known active CNS metastases and/or carcinomatous meningitis

• Able to provide written informed consent
• Advanced unresectable or metastatic solid tumor (Part 1, 2 \& 3 only)
• Advanced unresectable or metastatic HR+/HER2- breast cancer (Part 4 \& 5 only)
• Refractory to or unable to tolerate existing therapies (Part 1, 2 \& 4 only)
• Measurable or evaluable disease (Part 1, 2, \& 4 only).
• Measurable disease (Part 3 \& 5 only)
• Eighteen years of age or older
• ECOG status of 0 or 1
• Adequate organ function
• Patients with female reproductive organs must be surgically sterile, post- menopausal or willing to use effective contraception per protocol
• Patients who are capable of insemination must be willing to use highly effective contraception and to refrain from sperm donation during treatment and for 28 days after the last dose
• Able to swallow oral meds
• Willing to provide tumor tissue